Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.
Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve learning and memory in several pharmacological models of Alzheimer's disease (AD). In the present study, the effect of memantine on locomotor activity, social behavior, and spatial learning was assessed in a transgenic mouse model of AD. Eight-month-old male C57BL/6J mice carrying mutated human APP and PS1 genes (APP/PS1) and their nontransgenic (NT) litter mates were administered a therapeutic dose of memantine (30 mg/kg/day p.o.) for 2 to 3 weeks. At this age, APP/PS1 mice show elevated levels of beta-amyloid peptides in several brain regions. APP/PS1 mice exhibited less exploratory rearing and increased aggressive behavior compared with NT mice. In the water maze test for spatial learning, APP/PS1 mice had longer escape latencies to both hidden and visible platforms, but they did not differ from NT mice in their swimming speed. Memantine significantly improved the acquisition of the water maze in APP/PS1 mice without affecting swimming speed. Memantine did not affect either locomotor activity or aggressive behavior in either genotype. These data indicate that memantine improves hippocampus-based spatial learning in a transgenic mouse model of AD without producing nonspecific effects on locomotion/exploratory activity.
Minkeviciene
Rimante
R
Department of Neuroscience and Neurology, University of Kuopio, P.O. Box 1627, 70211 Kuopio, Finland.
Banerjee
Pradeep
P
Tanila
Heikki
H
D000374:Aggression / Q000187:drug effects; D000544:Alzheimer Disease; D000818:Animals; D015259:Dopamine Agents / Q000494:pharmacology; D006801:Humans; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D008559:Memantine / Q000097:blood / Q000494:pharmacology*; D051379:Mice; D008822:Mice, Transgenic; D013037:Spatial Behavior / Q000187:drug effects* / Q000502:physiology
D015259:Dopamine Agents; D008559:Memantine